Targeted Therapy for Neuroblastoma: ALK Inhibitors

J. H. Schulte; S. Schulte; L. C. Heukamp; K. Astrahantseff; H. Stephan; M. Fischer; A. Schramm; A. Eggert

doi:10.1055/s-0033-1357132

Klinische Pädiatrie, Inhaltsverzeichnis

Klin Padiatr 2013; 225(06): 303-308
DOI: 10.1055/s-0033-1357132

Review

Targeted Therapy for Neuroblastoma: ALK Inhibitors

Zielgerichtete Therapeutika zur Behandlung des Neuroblastoms: ALK-Inhibitoren

Authors

J. H. Schulte

¹German Cancer Consortium (DKTK), Germany

²Translational Neuro-Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany

³German Cancer Research Center (DKFZ), Heidelberg, Germany

⁴Department of Pediatric Oncology and Hematology, University Children’s Hospital Essen, Germany

⁵Centre for Medical Biotechnology, University Duisburg-Essen, Essen, Germany
S. Schulte

⁴Department of Pediatric Oncology and Hematology, University Children’s Hospital Essen, Germany
L. C. Heukamp

⁶Institute of Pathology, University Hospital Cologne, Germany
K. Astrahantseff

⁷Charité University Medicine, Campus Virchow Klinikum, Berlin, Germany
H. Stephan

⁴Department of Pediatric Oncology and Hematology, University Children’s Hospital Essen, Germany
M. Fischer

⁸Department of Pediatric Oncology and Hematology, Children’s Hospital, University of Cologne, Germany

⁹Center for Molecular Medicine Cologne (CMMC), University of Cologne, Germany
A. Schramm

⁴Department of Pediatric Oncology and Hematology, University Children’s Hospital Essen, Germany
A. Eggert

⁷Charité University Medicine, Campus Virchow Klinikum, Berlin, Germany

Abstract

Treatment for neuroblastoma, the most common extracranial childhood tumor, spans a broad range of aggressiveness that mirrors the risk profiles of disease subtypes, with high-risk neuroblastoma still presenting a clinical challenge. Currently, most patients with relapsed neuroblastoma die of disease and present a major challenge for treatment. New therapeutic options are urgently needed to improve patient survival. Activating mutations in the gene encoding the anaplastic lymphoma kinase (ALK) remain the most frequent druggable mutations identified in neuroblastomas to date. Preclinical data support an oncogene addiction of neuroblastoma cells to mutated ALK and demonstrate that ALK inhibitory therapy strongly combats tumor models. Most recently, pediatric phase I testing has been completed for the first approved ALK inhibitor, Crizotinib, showing very encouraging antitumoral results in neuroblastoma patients. Subsequently, an international phase I study with the second generation ALK inhibitor, LDK-378, will be launched that makes ALK inhibitory therapy also available to pediatric patients in Germany.

Zusammenfassung

Das Neuroblastom ist der häufigste extrakranielle Tumor des Kindesalters. Die Behandlung von Neuroblastomen der Hochrisikogruppe ist nach wie vor eine klinische Herausforderung, und die Prognose von Patienten mit einem Neuroblastomrezidiv ist nahezu infaust. Aktivierende Mutationen im Gen der Anaplastischen Lymphomkinase sind die häufigsten Mutationen in Neuroblastomen, die einer zielgerichteten Therapie zugänglich sind. Präklinische Daten stützen die Hypothese einer Onkogenabhängigkeit der Neuroblastomzellen von mutierter Anaplastischer Lymphomkinase (ALK) und deuten auf eine hohe Effizienz einer Therapie hin, die auf die Inhibition von ALK abzielt. Kürzlich konnte bereits eine pädiatrische Phase-I-Studie mit dem ALK-Inhibitor Crizotinib mit guten Ergebnissen auch im Hinblick auf eine antitumorale Wirkung bei Neuroblastomen abgeschlossen werden. In den nächsten Wochen wird darüber hinaus eine internationale pädiatrische Phase-I-Studie mit einem ALK-Inhibitor der zweiten Generation, LDK-378, initiiert werden. Damit können erstmals auch in Deutschland pädiatrische Patienten in einer Studie mit einem ALK-Inhibitor behandelt werden.

Key words

pediatric cancer - crizotinib - LDK-378 - LDK378

Schlüsselwörter

pädiatrische Krebserkrankung - Crizotinib - LDK-378 - LDK378

Volltext

Referenzen

References
1 Berry T, Luther W, Bhatnagar N et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012; 22: 117-130
2 Bochennek K, Esser R, Lehrnbecher T et al. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma. Klinische Padiatrie 2012; 224: 139-142
3 Bresler SC, Wood AC, Haglund EA et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Science translational medicine 2011; 3 108ra114
4 Butrynski JE, D’Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363: 1727-1733
5 Chen J, Jiang C, Wang S. LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor. Journal of medicinal chemistry 2013;
6 Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-974
7 Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nature reviews Cancer 2013; 13: 397-411
8 Cheung NK, Zhang J, Lu C et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012; 307: 1062-1071
9 Corbacioglu S. Early phase clinical trials in pediatric hematology and oncology. Klinische Padiatrie 2012; 224: 197-200
10 De Brouwer S, De Preter K, Kumps C et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clinical cancer research: an official journal of the American Association for Cancer Research 2010; 16: 4353-4362
11 Dienstmann R, Rodon J, Barretina J et al. Genomic medicine frontier in human solid tumors: prospects and challenges. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2013; 31: 1874-1884
12 Duijkers FA, Gaal J, Meijerink JP et al. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels. Cellular oncology 2011; 34: 409-417
13 Duijkers FA, Gaal J, Meijerink JP et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. The American journal of pathology 2012; 180: 1223-1231
14 Eggert A. Update: personalized diagnostics and therapies for pediatric cancer patients. Klinische Padiatrie 2013; 225: 107-109
15 Galkin AV, Melnick JS, Kim S et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007; 104: 270-275
16 George RE, Attiyeh EF, Li S et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2007; 2: e255
17 George RE, Sanda T, Hanna M et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-978
18 Gobel U, Korholz D, Bernig T et al. Treatment of children and adolecents with cancer after the application of the guide lines for good clinical practice in 2004 and the evaluation of new measurements. Klinische Padiatrie 2012; 224: 335-338
19 Grunewald TG, Greulich N, Kontny U et al. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klinische Padiatrie 2012; 224: 124-131
20 Heukamp LC, Thor T, Schramm A et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science translational medicine 2012; 4 141ra191
21 Janoueix-Lerosey I, Lequin D, Brugieres L et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-970
22 Janoueix-Lerosey I, Schleiermacher G, Michels E et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009; 27: 1026-1033
23 Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703
24 Lamant L, Pulford K, Bischof D et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000; 156: 1711-1721
25 Marsilje TH, Pei W, Chen B et al. Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials. Journal of medicinal chemistry 2013;
26 Martinsson T, Eriksson T, Abrahamsson J et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res 2011; 71: 98-105
27 McDermott U, Iafrate AJ, Gray NS et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008; 68: 3389-3395
28 Mestdagh P, Fredlund E, Pattyn F et al. An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene 2010; 29: 3583-3592
29 Mestdagh P, Fredlund E, Pattyn F et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010; 29: 1394-1404
30 Molenaar JJ, Domingo-Fernandez R, Ebus ME et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature genetics 2012; 44: 1199-1206
31 Molenaar JJ, Koster J, Zwijnenburg DA et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012; 483: 589-593
32 Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994; 263: 1281-1284
33 Mosse YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935
34 Mosse YP, Lim MS, Voss SD et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. The lancet oncology 2013; 14: 472-480
35 Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011; 71: 4403-4411
36 Oberthuer A, Berthold F, Warnat P et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006; 24: 5070-5078
37 Otto T, Horn S, Brockmann M et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009; 15: 67-78
38 Passoni L, Longo L, Collini P et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer research 2009; 69: 7338-7346
39 Pugh TJ, Morozova O, Attiyeh EF et al. The genetic landscape of high-risk neuroblastoma. Nature genetics 2013; 45: 279-284
40 Puissant A, Frumm SM, Alexe G et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer discovery 2013; 3: 308-323
41 Reiff T, Huber L, Kramer M et al. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development 2011; 138: 4699-4708
42 Sasaki T, Okuda K, Zheng W et al. The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers. Cancer Res 2010; 70: 10038-10043
43 Sausen M, Leary RJ, Jones S et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature genetics 2013; 45: 12-17
44 Schleiermacher G, Janoueix-Lerosey I, Ribeiro A et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010; 28: 3122-3130
45 Schulte JH, Bachmann HS, Brockmeyer B et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011; 17: 5082-5092
46 Schulte JH, Lindner S, Bohrer A et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 2013; 32: 1059-1065
47 Schulte JH, Marschall T, Martin M et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 2010; 38: 5919-5928
48 Schulte JH, Schowe B, Mestdagh P et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010; 127: 2374-2385
49 Schwab M, Alitalo K, Klempnauer KH et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305: 245-248
50 Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-1116
51 Simon T, Berthold F, Borkhardt A et al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatric blood & cancer 2011; 56: 578-583
52 Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566
53 Trochet D, Bourdeaut F, Janoueix-Lerosey I et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 2004; 74: 761-764
54 van Gaal JC, Flucke UE, Roeffen MH et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012; 30: 308-315
55 Witt O, Milde T, Deubzer HE et al. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klinische Padiatrie 2012; 224: 398-403
56 Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324-1334
57 Zhu S, Lee JS, Guo F et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 2012; 21: 362-373